Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Bullboard Posts
Comment by moneystarvedon May 27, 2013 11:46am
256 Views
Post# 21445444

RE: RE: RE: RE: AGM this morning

RE: RE: RE: RE: AGM this morning

I was at the  AGM, and it was actual very informative and reassuring.  

There were questions about the Financing (I am paraphrasing John's response to several questions);

Why? - It was quite simple, each group/fund/institution/pharma they talked to, their first question was do you have enough money to get through to final results for 007 (their answer was always no, but now it is yes).

Why at those terms? -most of the offering was to several strategic funds from the US.  5 Year, full warrant is essentially the market for such deals there.  The 5 year warrant is a virtual non-issue....either everyone is laughing once the end-point data is released (or not).

What about dilution? - Once again, yes there was some dilution (necessary dilution), however, should results be what people are hoping for, everyone will be jumping for joy and cashing in (potentially does that dilution mean a $5.50 share price…instead of a $6 sp?)

Really the company/stock is “binary”, it will either be a huge huge success (or it won’t).  Those that are in it, believe in the phase 1 results, and believe all the current signs for phase 2 results are positive ( at least not negative).  The fluctuation in share price can be taken as a buying opportunity, as truly nothing has changed.

Like most similar stocks at this phase….there should be a big speculative run up between now and the release of results (then a binary result).

After the AGM, I am more confident and assured that this stock is the right place for me, and it is only a matter of time between now and the results.  Hang on for the ride.

GL!

Imo ms

Bullboard Posts